Safety Profile of Controversial Vasculitis Drug Bolstered in New Trial
Dedicated Clinical Study Strengthens Safety Perception of Controversial
The AvacoStar study began in 2023. Vifor Fresenius Medical Care Renal Pharma initiated it. This collaboration involved Fresenius Medical Care and CSL Vifor. Vifor needed a specialized safety investigation. Five hundred four patients with high-activity AAV participated. The study took place in the UK and Germany. Doctors decided on avacopan or standard therapies. Two hundred fifty-four patients received avacopan. Two hundred fifty were treated with an alternative regimen.
Health news
Exercise and Mood: Italian Study Links Physical Activity to Lower Depression Symptoms
Screen Time in Childhood Linked to Unexpected Cognitive Boost in Teens, 8‑Year Study Shows
Workplace stress and anxiety are taking a heavy toll on employees, with one in three workers reporting that the strain is not easing
Daily Food Habit Tied to Lower Risk of Anxiety and DepressionAccording to Bernhard Hellmich, a Tübingen University physician, results were presented at the American College of Rheumatology (ACR) annual meeting in Orlando. Patients on avacopan showed a four-fold higher incidence of hepatic abnormalities. This was compared to those receiving rituximab (Rituxan) or cyclosporine. Importantly, these liver issues were not frequent or severe. Other significant adverse effects did not show higher prevalence with avacopan.
Avacopan faced serious hurdles this year. ChemoCentryx, the original developer, reevaluated key registration trial data. This reevaluation involved de-anonymizing data. It reclassified non-responders as responders. Initially, the primary endpoint was unmet. The data revision showed the endpoint was met.
Challenges Before the New Data
This potential data manipulation caused strong medical community reaction. Liver problems were known with avacopan. A label warning was deemed sufficient for risk management. However, the data reevaluation prompted action. The FDA asked Amgen to voluntarily withdraw the drug in the U. S. Amgen took control after acquiring ChemoCentryx in 2022.
Liver problems worsened in March. The FDA linked avacopan to eight global deaths. It also linked it to 76 cases of drug-induced liver injury. Fifty-four cases required hospital admission. Internationally, the data integrity controversy led to withdrawals. UK and European authorities ordered the withdrawal. The EU revoked its marketing authorization in August. Withdrawal in the UK was set for March of this year.
Amgen rejected the FDA's withdrawal request. The FDA did not mandate the withdrawal. New safety data and a recent Italian study confirming efficacy might sustain U. S. availability short-term.
Treatment Context and Study Details
Historically, AAV treatment used corticosteroids despite severe side effects. Rituximab and cyclosporine later joined the therapy arsenal. Avacopan received AAV approval in 2021. It was seen as a valuable complement to existing options.
Dr. Hellmich's AvacoStar analysis used data up to September 2025. Over 95% of participants continued their initial therapy. Average treatment duration was 16.2 months for avacopan. It was 12.7 months for alternatives. Patients averaged about 64 years old. Half were male. AAV subtypes were evenly split between granulomatosis with polyangiitis and microscopic polyangiitis. About one-quarter of patients were recently diagnosed. Half had severe renal impairment. About 20% had an estimated GFR below 15 mL/min/1.73 m2.
Regarding medical events, only liver injuries were significantly more common in the avacopan group (IRR 4.03; 95% CI 1.55 to 10.48). The absolute rate was low, reaching 0.07 per patient-year (95% CI 0.05-0.10). The most common events were serious infections. This rate was 0.14 per patient-year for avacopan. It was 0.18 per patient-year for rituximab or cyclosporine. These events included four categories of injuries.